Trial intelligence / Profile preview

Abatacept versus adalimumab on background methotrexate in early seropositive shared-epitope positive rheumatoid arthritis

2020-000350-96Phase 3Active

Sponsor: Bristol Myers Squibb
Start: May 2021
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, single-blind trial in rheumatoid arthritis (RA) comparing Abatacept plus methotrexate with Adalimumab plus methotrexate (2 arms). Primary endpoint: Proportion of SE+ participants meeting ACR50 response at Week 24. Started May 2021; status: active.

Drugs

abataceptadalimumabmethotrexate

Conditions

rheumatoid arthritis (RA)

Beyond the preview

Go deeper on 2020-000350-96.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2020-000350-96.